Zai Lab's share price drops despite revenue growth, hinting at profitability issues. The company may need to raise capital soon. Shareholders have faced an annual loss of 8% over the past five years.
Market expectations suggest a decline in Zai Lab's future revenue, possibly suppressing the P/S. Investors appear to anticipate limited growth, paying less for the stock. These conditions may continue to hinder the share price.
A team of US regulators is in the final stages of discussions with two Hong Kong accounting firms regarding their audits of mainland Chinese companies facing possible delisting from US exchanges, according to two sources familiar with the situation. This indicates the unprecedented review is nearing its end, and a report may come as soon as the end of this year, potenti...
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week. $アムジェン(AMGN.US)$Inc. is in advanced talks to buy drug company$Horizon Therapeutics(HZNP.US)$, according to people familiar with the matter, in a takeover likely to be valued at well over $20 billion and mark the largest healthcare merger of the year. $ROCHESTER RESOURCES LTD(RCTFF.US)$Holding AG presented new data from a ...
ザイ・ラボに関するコメント
wating
it's looking spicy
This is the stock u might wan to watch also good news
Holding up very well
Fly baby fly
A landmark review of audits of companies facing US delisting is coming to an end, with a report expected as soon as year’s end
This indicates the unprecedented review is nearing its end, and a report may come as soon as the end of this year, potenti...
コラムWeekly FDA Drug Pipeline Calendar (Dec 12 - Dec 17)
$アムジェン(AMGN.US)$ Inc. is in advanced talks to buy drug company $Horizon Therapeutics(HZNP.US)$, according to people familiar with the matter, in a takeover likely to be valued at well over $20 billion and mark the largest healthcare merger of the year.
$ROCHESTER RESOURCES LTD(RCTFF.US)$Holding AG presented new data from a ...
まだコメントはありません